Overview
Safety and Efficacy Study of BRIMOCHOL™ in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2023-03-31
2023-03-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
Safety and Efficacy Study of BRIMOCHOL™ in Subjects With Emmetropic Phakic and Pseudophakic PresbyopiaPhase:
Phase 3Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Visus TherapeuticsTreatments:
Brimonidine Tartrate
Carbachol
Criteria
Inclusion Criteria:- Male or female in good general health
- Must have presbyopia
Exclusion Criteria:
- History of allergic reaction to the study drug or any of its components
- Any disease or medical condition that, in the opinion of the Investigator, would
prevent the subject from participating in the study or might confound study results